Profile data is unavailable for this security.
About the company
iBio, Inc. is a developer of next-generation biopharmaceuticals using its proprietary artificial intelligence (AI)-Driven Discovery Platform and FastPharming Manufacturing System. The Company is focusing its technologies on the research and development of novel products at its Drug Discovery Center in California. The Company through its FastPharming Manufacturing System and GlycaneeringSM Technologies develop its portfolio of proprietary biologic drug candidates. The Company operates through two segments: Biopharmaceuticals, and Bioprocessing. Its Biopharmaceuticals segment is engaged in large molecule discovery, development, and licensing activities. Its Bioprocessing segment is engaged in contract development and manufacturing services for recombinant proteins. Its pipeline includes IBIO-100, IBIO-101, IBIO-202, and IBIO-400. Its subsidiary, iBio CDMO LLC, provides FastPharming Contract Development and Manufacturing Services along with GlycaneeringSM Development Services.
- Revenue in USD (TTM)61.00k
- Net income in USD-41.43m
- LocationIbio Inc600 Madison Avenue, Suite 1601NEW YORK 10022-1737United StatesUSA
- Phone+1 (302) 355-0650
- Fax+1 (302) 356-1173
Mergers & acquisitions
|Acquired company||Deal status||Date||Date /|
|IBIO:ASQ since |
|Rubryc Therapeutics Inc||Deal completed||21 Sep 2022||21 Sep 2022Deal completed||-91.15%||6.00m|